British scientists are launching a world-first clinical trial for a vaccine that could change the way the world immunises. Instead of needing to be kept cold, this new tetanus-diphtheria vaccine remains stable at room temperature—offering a game-changing solution for communities where refrigeration is unreliable or unavailable.
The fridge-free vaccine, created by UK biotech company Stablepharma, is currently being tested on volunteers at University Hospital Southampton. Backed by government support, the team hopes to make it globally available by 2027. If successful, it could eliminate vast amounts of vaccine waste, lower carbon emissions, and vastly improve access in remote regions. Scientists say this innovation could pave the way for transforming dozens of existing vaccines into thermostable forms, bringing us one step closer to equitable healthcare for all.